Reacting to an emerging safety threat: West Nile virus in North America

Developments in Biologicals

Volumn 127, Issue , 2007, Pages 43-58

  Stramer, S L ^a  

^a AMERICAN RED CROSS   (United States)

Author keywords

Blood donation; Neuroinvasive disease; Nucleic acid testing; West Nile virus

Indexed keywords

BLOOD BANK; BLOOD TRANSFUSION; COMMUNICABLE DISEASE; CONFERENCE PAPER; DISEASE TRANSMISSION; EPIDEMIOLOGY; HUMAN; ISOLATION AND PURIFICATION; MASS SCREENING; METHODOLOGY; NORTH AMERICA; VIREMIA; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

BLOOD BANKS; BLOOD TRANSFUSION; COMMUNICABLE DISEASES, EMERGING; HUMANS; MASS SCREENING; NORTH AMERICA; SEROEPIDEMIOLOGIC STUDIES; VIREMIA; WEST NILE FEVER; WEST NILE VIRUS;

EID: 34247146771     PISSN: 14246074     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (46)

1. Peterson LR, Marfin AA: West Nile virus: a primer for the clinician. Ann Intern Med 2002; 137: 173-179.
2. Centers for Disease Control and Prevention. West Nile virus activity - United States, January 1-December 1, 2005. MMWR Morb Mortal Wkly Rep 2005; 54: 1253-1256.
3. Kreil TR, Berting A, Kistner O, Kindermann J: West Nile virus and the safety of plasma derviatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003; 43: 1023-1028.
4. Petersen LR, Hayes EB: Westward ho ? The spread of West Nile virus. N Engl J Med 2004; 351: 2257-2259.
5. Centers for Disease Control and Prevention. 2005 West Nile virus activity in the United States, February 23, 2006. http://www.cdc.gov/ncidod/dvbid/ westnile/serv&control.htm.
6. Zucker JR: Changing patterns of autochthonous malaria transmission in the United States: a review of recent outbreaks. Emerg Inf Dis 1996; 2:37-43.
7. Hayes EB, Komar N, Nasci RS, Montgomery SP, O'Leary DR, Campbell GL: Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis 2005; 11: 1167-1173.
8. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL: Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis 2005; 11: 1174-1179.
9. Centers for Disease Control and Prevention. Update: investigations of West Nile virus infection in recipients of organ transplantation and blood transfusion. MMWR Morb Mortal Wkly Rep 2002; 51: 833-836.
10. Iwamoto M, Jernigan DB, Guasch A, Trepka MA, Blackmore CG, Hellinger WC, et al: Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003; 348: 2196-2203.
11. Food and Drug Administration: Guidance for industry: assessing donor suitability and blood and blood product safety in cases of known or suspected West Nile virus infection. Rockville (MD): Center for Biologics Evaluation and Research (CBER), 2005 June.
12. Pealer LN, Marfin AA, Petersen LR, Lanciotti RS, Page PL, Stramer SL, et al: Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003; 349 (13): 1236-1245.
13. Mostashari F, Bunning M, Kitsutani PT, Singer DA, Nash D, Cooper MJ, et al: Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 2001; 358: 261-264.
14. Orton, SL, Stramer SL, Dodd RY: Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion 2006; 46: 272-277.
15. Busch, MP, Wright DJ, Tobler LH, Stramer SL, Kleinman SH, Prince HE, et al.: West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg Infect Dis 2006; 12 (3): 395-402. www.cdc.gov/ncidod/EID/vol12no03/05-1287.htm.
16. Dodd RY: Emerging infections, transfusion safety, and epidemiology. N Engl J Med 2003; 349: 1205-1206.
17. Stramer SL, Fang CT, Foster GA, Wagner AG, Brodsky JP, Dodd RY: West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med 2005; 353: 451-459.
18. Busch MP, Caglioti S, Robertson EF, McAuley JD, Tobler LH, Kamel H, et al: Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med 2005; 353: 460-467.
19. Food and Drug Administration. Product Approval Information - Licensing Action. Dec l,2005.http://www.fda.gov/cber/approvltr/wnvgen120105L.htm.
20. Busch MP, Tobler L, Saldanha J, Caglioti S, Shyamala V, Linnen JM, et al: Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003. Transfusion 2005; 45: 492-499.
21. Gen-Probe, Inc. Gen-Probe submits regulatory application for use of Procleix® TIGRIS® system to screen donation blood for West Nile virus, April 24, 2006. http://biz.yahoo.com/prnews/060420/lath037.html?.v=49.
22. Hillyer CD, Lipton KS: Joint statement of AABB, America's Blood Centers and American Red Cross on testing for West Nile virus. AABB Bulletin No, 06-02. Bethesda, MD: AABB, 2006:1-2.
23. Biggerstaff BJ, Petersen LR: Estimated risk of transmission of the West Nile virus through blood transfusion in the US, 2002. Transfusion 2003; 43: 1007-1017.
24. Stramer SL, Beyers ML, Wagner AG, Dille, BJ, Dawson GJ, Schochetman G, et al: West Nile virus (WNV) RNA prevalence in blood donations during the 2002 US epidemic. Transfusion 2003; 43 (Suppl. 9S) 3A: S10.
25. Custer B, Tomasulo PA, Murphy EL, Caglioti S, Harpool D, McEvoy D, Busch MP. Triggers for switch-ing from minipool testing by nucleic acid technology to individual-donation nucleic acid testing for West Nile virus: analysis of 2003 data to inform 2004 decision making. Transfusion 2004; 44 (11): 1547-1554.
26. Montgomery SP, Brown JA, Kuehnert M, Smith TL, Crall N, Lanciotti RS, et al: Transfusion-associated transmission of West Nile virus, United States 2003-2005. Transfusion 2006; 46: 2038-2046.
27. Centers for Disease Control and Prevention. Update: West Nile virus screening of blood donations and transfusion-associated transmission - United States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53: 281-284.
28. Macedo de Oliveira A, Beecham BD, Montgomery SP, Lanciotti RS, Linnen JM, Giachetti C, Pietrelli LA, Stramer SL, Safranek TJ: West Nile virus blood transfusion-related infection despite nucleic acid testing. Transfusion 2004; 44: 1695-1699.
29. Centers for Disease Control and Prevention. Transfusion - associated transmission of West Nile virus -Arizona, 2004. MMWR Morb Mortal Wkly Rep 2004; 53: 842-844.
30. Centers for Disease Control and Prevention. West Nile virus infections in organ transplant recipient -New York and Pennsylvania, August-September, 2005. MMWR Morb Mortal Wkly Rep 2005; 54: 1021-1023.
31. Rios M, Daniel S, Stramer SL, Caglioti S, Wood O, Hewlett IK: West Nile virus NAT-positive human plasma containing WNV-IgM and IgG antibodies can infect Vero cells and human primary macrophages in culture. Transfusion 2005; 45 (Suppl. 3S): 3A.
32. Rios M, Daniel S, Wood O, Hewlett IK, Caglioti S, Stramer SL: Further studies of the infectivity of West Nile virus (WNV) in the presence of human specific antibodies. Abstract submitted 2006.
33. th National Conference on West Nile virus, San Francisco, Calif., February, 2006.
34. th National Conference on West Nile virus in the United States, San Jose, Calif., February, 2005.
35. Roehrig JT, Nash D, Maldin B, Labowitz A, Martin DA, Lanciotti RS, Campbell GL: Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis 2003; 9: 376-379.
36. Prince HE, Tobler LH, Lape-Nixon M, Foster GA, Stramer SL, Busch MP: Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors. J Clin Microbiol 2005; 43: 4316-4320.
37. Food and Drug Administration. Guidance for industry: recommendations for the assessment of donor suitability and blood and blood product safety in cases of known or suspected West Nile virus infection. Rockville (MD): Center for Biologies Evaluation and Research (CBER), 2002 Oct.
38. Food and Drug Administration. Revised recommendations for the assessment of donor suitability of donor suitability and blood and blood product safety in cases of known or suspected Westn Nile virus infection. Rockville (MD): Center for Biologies Evaluation and Research (CBER), 2003 May.
39. Food and Drug Administration. Guidance for industry: revised recommendations for the assessment of donor suitability and blood and blood product safety in cases of known or suspected West Nile virus infection. Rockville (MD): Center for Biologies Evaluation and Research (CBER), 2005 April.
40. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP: Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004; 351: 760-768.
41. Custer B, Busch MP, Marfin AA, Petersen LR: The cost-effectiveness of screening the US blood supply for West Nile virus. Ann Intern Med. 2005; 143 (7): 486-492.
42. Korves CT, Goldie SJ, Murray MB: Cost-effectiveness of alternative blood-screening strategies for West Nile virus in the United States. PLoS Med. 2006; 3 (2) e21: 0211-0221.
43. Kuehn BM: Studies propose targeted screening of blood for West Nile virus. JAMA 2006; 295 (11): 1235-1236.
44. Aubuchon, JP: Meeting transfusion safety expectation. Ann Intern Med 2005; 143 (7) 537-538.
45. Stramer SL, Custer B, Busch MP, Dodd RY: Strategies for testing blood donors for West Nile virus. Transfusion 2006; 46: 2036-2037.
46. Ness PM, Lipton KS: Selective transfusion protocols: errors and accidents waiting to happen. Transfusion 2001; 41: 713-715.